SCHEMBL915730

SCHEMBL915730

CCCCC(=O)OC(C)OC(=O)C(N)[C@H]1CC[C@H](C(=O)O)CC1

nearest known ligand 0.41

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.41
ALDH1A1 P00352 1/20 0.35
MAPT P10636 2/20 0.33
MAPK1 P28482 1/20 0.33
PRKCA P17252 4/20 0.33
PRKCE Q02156 1/20 0.33
PRKCQ Q04759 1/20 0.33
PRKCD Q05655 1/20 0.33
NAAA Q02083 2/20 0.32
ANPEP P15144 1/20 0.32
ENPEP Q07075 1/20 0.32
CYP1A2 P05177 1/20 0.32
PAM P19021 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4699739 1.00 LMNA (0.41) LMNAALDH1A1MAPTMAPK1PRKCA
SCHEMBL4700619 0.92 LMNA (0.33) LMNAALDH1A1ANPEPENPEP
SCHEMBL915707 0.92 LMNA (0.33) LMNAALDH1A1ANPEPENPEP
SCHEMBL4698134 0.89 LMNA (0.40) LMNAALDH1A1MAPTMAPK1PRKCA
SCHEMBL924545 0.89 LMNA (0.40) LMNAALDH1A1MAPTMAPK1PRKCA
SCHEMBL915947 0.88 ANPEP (0.36) LMNAANPEPENPEP
SCHEMBL3255171 0.83 MMP1 (0.37) LMNAANPEPENPEP
SCHEMBL914423 0.83 MMP1 (0.37) LMNAANPEPENPEP
SCHEMBL915150 0.81 ANPEP (0.35) LMNAANPEPENPEP
SCHEMBL915152 0.81 ANPEP (0.35) LMNAANPEPENPEP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1919859-B1 ACYLOXYALKYL CARBAMATE PRODRUGS OF TRANEXAMIC ACID AND USE XENOPORT INC (US) 2010-06-02 EP claimed
US-7351740-B2 Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use XENOPORT, INC. (US) 2008-04-01 US claimed
US-20070027210-A1 Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use XENOPORT, INC. 2007-02-01 US claimed
US-8372881-B2 Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use XENOPORT, INC. (US) 2013-02-12 US disclosed
US-20110060040-A1 USES OF ACYLOXYALKYL CARBAMATE PRODRUGS OF TRANEXAMIC ACID XENOPORT, INC. 2011-03-10 US disclosed
US-20110009483-A1 ACYLOXYALKYL CARBAMATE PRODRUGS OF TRANEXAMIC ACID, METHODS OF SYNTHESIS AND USE XENOPORT, INC. (US) 2011-01-13 US disclosed
US-7777070-B2 Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use XENOPORT, INC. (US) 2010-08-17 US disclosed
EP-1919859-B1 ACYLOXYALKYL CARBAMATE PRODRUGS OF TRANEXAMIC ACID AND USE XENOPORT INC (US) 2010-06-02 EP disclosed
US-20100036148-A1 Acyloxyalkyl Carbamate Prodrugs of Tranexamic Acid, Methods of Synthesis and Use XENOPORT, INC. (US) 2010-02-11 US disclosed
US-7592369-B2 Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use XENOPORT, INC. (US) 2009-09-22 US disclosed
US-20080153898-A1 ACYLOXYALKYL CARBAMATE PRODRUGS OF TRANEXAMIC ACID, METHODS OF SYNTHESIS AND USE XENOPORT, INC. 2008-06-26 US disclosed
EP-1919859-A2 ACYLOXYALKYL CARBAMATE PRODRUGS OF TRANEXAMIC ACID, METHODS OF SYNTHESIS AND USE Xenoport, Inc. (US) 2008-05-14 EP disclosed
US-7351740-B2 Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use XENOPORT, INC. (US) 2008-04-01 US disclosed
US-20070027210-A1 Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use XENOPORT, INC. 2007-02-01 US disclosed
WO-2007002013-A2 ACYLOXYALKYL CARBAMATE PRODRUGS OF TRANEXAMIC ACID, METHODS OF SYNTHESIS AND USE XENOPORT, INC. (US) 2007-01-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110060040-A1 USES OF ACYLOXYALKYL CARBAMATE PRODRUGS OF TRANEXAMIC ACID PIGS, CPS1, ACMSD LMNA 1328/4885ALDH1A1 1745/4885MAPT 4566/4885
US-20070027210-A1 Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use ACMSD, APEH, CPS1 LMNA 946/4885ALDH1A1 2016/4885MAPT 3737/4885
US-20110009483-A1 ACYLOXYALKYL CARBAMATE PRODRUGS OF TRANEXAMIC ACID, METHODS OF SYNTHESIS AND USE ACMSD, APEH, CPS1 LMNA 946/4885ALDH1A1 2016/4885MAPT 3737/4885
US-20080153898-A1 ACYLOXYALKYL CARBAMATE PRODRUGS OF TRANEXAMIC ACID, METHODS OF SYNTHESIS AND USE ACMSD, APEH, CPS1 LMNA 946/4885ALDH1A1 2016/4885MAPT 3737/4885
US-20100036148-A1 Acyloxyalkyl Carbamate Prodrugs of Tranexamic Acid, Methods of Synthesis and Use ACMSD, APEH, CPS1 LMNA 946/4885ALDH1A1 2016/4885MAPT 3737/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.